Healthcare • Drug Manufacturers - Specialty & Generic
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if LFCR is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
16 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 1
99 filers reported a long position in LFCR for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| WYNNEFIELD CAPITAL INC | $24.7M | 4.7M | Unchanged |
| Legion Partners Asset Management, LLC | $23.4M | 4.5M | Unchanged |
| Greenhaven Road Investment Management, L.P. | $16.8M | 3.2M | -9.8% |
| 325 CAPITAL LLC | $15.2M | 2.9M | +33.9% |
| BlackRock, Inc. | $10.6M | 2M | +7.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.8M | 1.3M | -0.1% |
| GEODE CAPITAL MANAGEMENT, LLC | $4.5M | 855.5K | +5% |
| MORGAN STANLEY | $4M | 769.4K | +0.6% |
| STATE STREET CORP | $3.5M | 668K | +4.1% |
| Quinn Opportunity Partners LLC | $2.4M | 453.5K | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.